Trametinib (Mekinist) and BRAF V600 Cancer Therapy

BRAF V600-mutated cancer therapy comparison with special focus on trametinib (Mekinist)

Including:

* Trametinib molecular and clinical development, side effects
* Role of BRAF V600E/K in the Ras/Raf/MAPK (MEK)/ERK pathway
* Trametinib Indications: metastatic melanoma, thyroid, non-small cell lung cancer
* Trametinib is showing promise in low-grade glioma, neuroblastoma, solid tumors and NF-1
* Dabrafenib+trametinib, vemurafenib+cobimetinib, encorafenib+binimetinib clinical trial results
compared with monotherapy and (dacarbazine or paclitaxel) chemotherapy

PPT can be downloaded at:

Notes & References can be downloaded at:

Here's a link to my 12-part Cancer Prevention Education Course

Here's a link to my 9-part Cancer Prevention Education Course for Health Professionals:

Please note: This presentation is not a substitute for professional individualized advice.